Back to mobile site

Piper Sandler Discusses Ventyx Biosciences (VTYX) KOL Takeaways Into Upcoming Deucravacitinib PDUFA

August 19, 2022 8:57 AM EDT Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $50.00 price target on Ventyx Biosciences Inc (NASDAQ: VTYX) ahead ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login